Clinical Trial Update: Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports HuL001 being studied in relapsed/refractory multiple myeloma in Phase 1/2, with enrollment currently by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• HuL001

Snippet

Sponsor: HuniLife Biotechnology, Inc. | Conditions: Multiple Myeloma Refractory | Phase 1, Phase 2 | Status: ENROLLING_BY_INVITATION